{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-023842","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.976693+00:00","generated_at":"2026-06-06T02:24:59.978288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics Q1 net loss $11.2M; NORSE EIGHT underway, SPA agreed, $172M financing","bullets":["Net loss for Q1 FY2024 was $11.2M ($0.04/sh), compared to $18.7M ($0.08/sh) in prior year.","Cash and equivalents at Dec 31, 2023: $10.4M; private placements for up to $172M (subject to shareholder approval).","FDA SPA agreed on NORSE EIGHT protocol; first subject dosed Jan 2024. Success would satisfy second clinical trial requirement from CRL.","BLA resubmission for ONS-5010 expected by end of CY2024; EU MAA decision targeted first half 2024.","Company working to resolve CMC comments from CRL; expects resolution before NORSE EIGHT completion."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-023842","json":"https://secwatch.observer/filing/0001104659-24-023842.json","markdown":"https://secwatch.observer/filing/0001104659-24-023842.md","text":"https://secwatch.observer/filing/0001104659-24-023842.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/0001104659-24-023842-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/tm246210d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:24:59.978288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"812d1a3404447afb39be3b0ae7ceafb61c3bd8b9","claim":"Outlook Therapeutics, Inc. reported first fiscal quarter ended December 31, 2023 results: net income $11.2 million, EPS $0.04 per basic and diluted share.","evidence_excerpt":"For the fiscal first quarter ended December 31, 2023, Outlook Therapeutics reported a net loss attributable to common stockholders of $11.2 million, or $0.04 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/0001104659-24-023842-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first fiscal quarter ended December 31, 2023"},{"label":"Net income","value":"$11.2 million"},{"label":"EPS","value":"$0.04 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}